For: | Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1724-1745 [PMID: 24587651 DOI: 10.3748/wjg.v20.i7.1724] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i7/1724.htm |
Number | Citing Articles |
1 |
Min Qiu, Jiahuan Li, Shali Hao, Haoxiao Zheng, Xiaojie Zhang, Hailan Zhu, Xiaolin Zhu, Yunzhao Hu, Xiaoyan Cai, Yuli Huang. Non-alcoholic fatty liver disease is associated with a worse prognosis in patients with heart failure: A pool analysis. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1167608
|
2 |
Flavia Vernin de Oliveira Terzi, Gabriel Cordeiro Camargo, Daniella Braz Parente, Ana Maria Pittella, Gilberto Silva-Junior, Gabrielle Gonçalves de Novaes, Jaime Araújo Oliveira Neto, Julia Machado Barroso, Martha Valéria Tavares Pinheiro, Adriana Soares Xavier de Brito, Renée Sarmento de Oliveira, Rosana Souza Rodrigues, Renata de Mello Perez, Andréa Silvestre de Sousa, Renata Junqueira Moll-Bernardes. How Cardiac Fibrosis Assessed via T1 Mapping Is Associated with Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine 2023; 12(23): 7381 doi: 10.3390/jcm12237381
|
3 |
Wen Wen, Hua Fan, Shenghui Zhang, Siqi Hu, Chen Chen, Jiake Tang, Yao You, Chunyi Wang, Jie Li, Lin Luo, Yongran Cheng, Mengyun Zhou, Xuezhi Zhao, Tao Tan, Fangfang Xu, Xinyan Fu, Juan Chen, Peng Dong, Xingwei Zhang, Mingwei Wang, Yan Feng. Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease. The American Journal of the Medical Sciences 2024; 368(6): 557 doi: 10.1016/j.amjms.2024.06.022
|
4 |
Luis Antonio Díaz, Eduardo Fuentes-López, Gustavo Ayares, Francisco Idalsoaga, Jorge Arnold, Andrea Márquez-Lomas, Carolina A Ramírez, María Paz Medel, Francisca Viñuela, Lucas Lacalle, Juan Pablo Roblero, Catterina Ferreccio, Mariana Lazo, Mayur Brahmania, Ashwani K Singal, Melisa Dirchwolf, Nahum Méndez-Sánchez, Norberto Chavez-Tapia, Patricia Guerra, Juan Carlos Restrepo, Claudia P Oliveira, Julissa Lombardo, Abel Sánchez, Martín Elizondo, Martín Tagle, Martín Padilla, Marco Sánchez, Enrique Carrera, Marcos Girala, Omega Chery, Marlen Castellanos-Fernández, Francisco Barrera, Jeffrey V Lazarus, Patrick S Kamath, Ramon Bataller, Marco Arrese, Juan Pablo Arab. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. The Lancet Gastroenterology & Hepatology 2022; 7(6): 552 doi: 10.1016/S2468-1253(22)00008-5
|
5 |
Luca Miele, Giovanni Targher. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. Expert Review of Gastroenterology & Hepatology 2015; 9(10): 1243 doi: 10.1586/17474124.2015.1074860
|
6 |
Ping Wang, Hua Qiang, Yan Song, Ying Dang, Hui Luan, Lifei Cao, Qing Cui, Gang Tian. Association between Nonalcoholic Fatty Liver and Gensini Score in Patients with Coronary Heart Disease: A Cross-Sectional Study. Cardiology 2019; 144(3-4): 90 doi: 10.1159/000502111
|
7 |
Seung Up Kim, Dongbeom Song, Ji Hoe Heo, Joonsang Yoo, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Joon Kim, Kwang-Hyub Han, Young Dae Kim. Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. Atherosclerosis 2017; 260: 156 doi: 10.1016/j.atherosclerosis.2017.02.005
|
8 |
Isabel Hidalgo, Salvador Fonseca-Coronado, Guillermo Ceballos, Eduardo Meaney, Nayelli Nájera. Dislipidemias, hígado graso y enfermedad cardiovascular. Cardiovascular and Metabolic Science 2022; 33(3): 134 doi: 10.35366/107628
|
9 |
Søren Møller, Nina Kimer, Thit Kronborg, Josephine Grandt, Jens Dahlgaard Hove, Mads Barløse, Lise Lotte Gluud. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Seminars in Liver Disease 2021; 41(03): 235 doi: 10.1055/s-0041-1725022
|
10 |
Christopher D. Byrne, Giovanni Targher. NAFLD: A multisystem disease. Journal of Hepatology 2015; 62(1): S47 doi: 10.1016/j.jhep.2014.12.012
|
11 |
Guoxin Huang, Hui Zhou, Chao Shen, Yihui Sheng, Ruyu Xue, Chen Dong, Shaoyan Zhang. Bi-directional and temporal relationship between elevated alanine aminotransferase and hypertension in a longitudinal study of Chinese adults. Clinical and Experimental Hypertension 2021; 43(8): 750 doi: 10.1080/10641963.2021.1960364
|
12 |
Kyung Eun Yun, Ga Eun Nam, Jisun Lim, Hye Soon Park, Yoosoo Chang, Hyun-Suk Jung, Chan-Won Kim, Byung-Joon Ko, Eun Chul Chung, Hocheol Shin, Seungho Ryu, Giovanni Targher. Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study. PLOS ONE 2016; 11(7): e0158710 doi: 10.1371/journal.pone.0158710
|
13 |
Nicholas Scalzo, Mehtap Canastar, Edward Lebovics. Part 1: Disease of the Heart and Liver. Cardiology in Review 2022; 30(3): 111 doi: 10.1097/CRD.0000000000000379
|
14 |
Steven M. Elzein, Elizabeth W. Brombosz, Sudha Kodali. Cardiac abnormalities pre- and post-liver transplantation for metabolic dysfunction-associated steatohepatitis – Evidence and special considerations. Journal of Liver Transplantation 2024; 15: 100228 doi: 10.1016/j.liver.2024.100228
|
15 |
Consuêlo Padilha VILAR, Helma Pinchemel COTRIM, Gesira Soares Assis FLORENTINO, Gerson BRAGAGNOLI, Paulo Adriano SCHWINGEL, Cibelle Padilha Vilar BARRETO. NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CORONARY DISEASE FROM A BRAZIL NORTHEAST AREA. Arquivos de Gastroenterologia 2015; 52(2): 111 doi: 10.1590/S0004-28032015000200007
|
16 |
Ryan D. Sheldon, Grace M. Meers, E. Matthew Morris, Melissa A. Linden, Rory P. Cunningham, Jamal A. Ibdah, John P. Thyfault, M. Harold Laughlin, R. Scott Rector. eNOS deletion impairs mitochondrial quality control and exacerbates Western diet-induced NASH. American Journal of Physiology-Endocrinology and Metabolism 2019; 317(4): E605 doi: 10.1152/ajpendo.00096.2019
|
17 |
James J DiNicolantonio, Mark McCarty, James OKeefe. Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance. Open Heart 2019; 6(1): e000890 doi: 10.1136/openhrt-2018-000890
|
18 |
Maureen Whitsett, Jane Wilcox, Amy Yang, Lihui Zhao, Mary Rinella, Lisa B. VanWagner. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy‐proven nonalcoholic steatohepatitis. Liver International 2019; 39(5): 933 doi: 10.1111/liv.14018
|
19 |
Hayato Urushima, Yasuaki Sanada, Miki Sakaue, Yuji Matsuzawa, Toshinori Ito, Kazuhisa Maeda. Maltitol Prevents the Progression of Fatty Liver Degeneration in Mice Fed High-Fat Diets. Journal of Medicinal Food 2015; 18(10): 1081 doi: 10.1089/jmf.2014.3380
|
20 |
Aki Juhani Käräjämäki, Janne Hukkanen, Olavi Ukkola. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. Annals of Medicine 2018; 50(5): 371 doi: 10.1080/07853890.2018.1492147
|
21 |
Lisa B. VanWagner, Jane E. Wilcox, Hongyan Ning, Cora E. Lewis, John Jeffrey Carr, Mary E. Rinella, Sanjiv J. Shah, Joao A. C. Lima, Donald M. Lloyd‐Jones. Longitudinal Association of Non‐Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. Journal of the American Heart Association 2020; 9(4) doi: 10.1161/JAHA.119.014279
|
22 |
María Esther Rubio-Ruiz, Ana Elena Peredo-Escárcega, Agustina Cano-Martínez, Verónica Guarner-Lans. An Evolutionary Perspective of Nutrition and Inflammation as Mechanisms of Cardiovascular Disease. International Journal of Evolutionary Biology 2015; 2015: 1 doi: 10.1155/2015/179791
|
23 |
Sven M. Francque, Denise van der Graaff, Wilhelmus J. Kwanten. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. Journal of Hepatology 2016; 65(2): 425 doi: 10.1016/j.jhep.2016.04.005
|
24 |
Sergio Fresneda, Manuela Abbate, Carla Busquets-Cortés, Arturo López-González, Pilar Fuster-Parra, Miquel Bennasar-Veny, Aina M. Yáñez. Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study. Biology of Sex Differences 2022; 13(1) doi: 10.1186/s13293-022-00475-7
|
25 |
Wen Cao, Xing An, Longfei Cong, Chaoyang Lyu, Qian Zhou, Ruijun Guo. Application of Deep Learning in Quantitative Analysis of 2‐Dimensional Ultrasound Imaging of Nonalcoholic Fatty Liver Disease. Journal of Ultrasound in Medicine 2020; 39(1): 51 doi: 10.1002/jum.15070
|
26 |
Stefano Ballestri, Fabio Nascimbeni, Enrica Baldelli, Alessandra Marrazzo, Dante Romagnoli, Amedeo Lonardo. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Advances in Therapy 2017; 34(6): 1291 doi: 10.1007/s12325-017-0556-1
|
27 |
Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo. Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies. Frontiers in Nutrition 2024; 11 doi: 10.3389/fnut.2024.1355732
|
28 |
Carmelo García‐Monzón, Javier Vargas‐Castrillón, José Luís Porrero, María Teresa Alonso, Oscar Bonachía, María José Castillo, Alberto Marcos, Esther Quirós, Beatriz Ramos, Carlos Sánchez‐Cabezudo, Sol Villar, Alicia Sáez, Javier Rodríguez de Cía, Elvira del Pozo, Lorena Vega‐Piris, Susana Soto‐Fernández, Oreste Lo Iacono, María Eugenia Miquilena‐Colina. Prevalence and risk factors for biopsy‐proven non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. Liver International 2015; 35(8): 1983 doi: 10.1111/liv.12813
|
29 |
Ludovico ABENAVOLI, Roman MYAZIN, Sharmila FAGOONEE, Pietro CINAGLIA, Francesco LUZZA, Rinaldo PELLICANO, Dmitry EMELYANOV. Treatment with phosphatidylcholine of patients with nonalcoholic fatty liver disease: a prospective pilot study. Minerva Gastroenterology 2022; 68(4) doi: 10.23736/S2724-5985.21.03066-7
|
30 |
Qun Liu, Shou-Sheng Liu, Zhen-Zhen Zhao, Ben-Tian Zhao, Shui-Xian Du, Wen-Wen Jin, Yong-Ning Xin. TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population. Lipids in Health and Disease 2019; 18(1) doi: 10.1186/s12944-019-1108-2
|
31 |
Sheila Gato, Vanessa García-Fernández, Antonio Gil-Gómez, Ángela Rojas, Rocío Montero-Vallejo, Rocío Muñoz-Hernández, Manuel Romero-Gómez. Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome. European Cardiology Review 2024; 19 doi: 10.15420/ecr.2023.26
|
32 |
Zahra Eslami, Samaneh Sadat Aghili, Amir Ghaleh Ghafi. Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients. Chonnam Medical Journal 2024; 60(1): 13 doi: 10.4068/cmj.2024.60.1.13
|
33 |
Altan Onat, Günay Can, Ayşem Kaya, Tuğba Akbaş, Fatma Özpamuk-Karadeniz, Barış Şimşek, Hakan Çakır, Hüsniye Yüksel. Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality. World Journal of Gastroenterology 2015; 21(48): 13555-13565 doi: 10.3748/wjg.v21.i48.13555
|
34 |
Alessandro Mantovani, Stefano Ballestri, Amedeo Lonardo, Giovanni Targher. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences 2016; 61(5): 1246 doi: 10.1007/s10620-016-4040-6
|
35 |
T. Yu. Demidova, M. Ya. Izmailova, D. V. Skuridina. Extraglycemic effects of NGLT2 inhibitors and effects on NAFLD as an effective way to improve cardiorenal prognosis in patients with type 2 diabetes. FOCUS. Endocrinology 2023; 4(3): 62 doi: 10.15829/2713-0177-2023-3-17
|
36 |
Motoi TAMURA, Jun WATANABE, Sachiko HORI, Atsuko INOSE, Yuji KUBO, Tomotsugu NOGUCHI, Takanobu NISHIKAWA, Masaya IKEZAWA, Risa ARAKI, Masuko KOBORI. Effects of a high-γ-polyglutamic acid-containing natto diet on liver lipids and cecal microbiota of adult female mice. Bioscience of Microbiota, Food and Health 2021; 40(4): 176 doi: 10.12938/bmfh.2020-061
|
37 |
Yu Zhang, Peifei Li, Min Miao, Yi Liu, Yue Pan, Lu Xu, Zhongwei Zhu, Chengfu Xu, Lei Xu. Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/5628749
|
38 |
Stefano Ballestri, Dante Romagnoli, Fabio Nascimbeni, Giampiero Francica, Amedeo Lonardo. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Review of Gastroenterology & Hepatology 2015; 9(5): 603 doi: 10.1586/17474124.2015.1007955
|
39 |
Miwa Kawanaka, Ken Nishino, Mayuko Kawada, Katsunori Ishii, Tomohiro Tanikawa, Noriiyo Urata, Mitsuhiko Suehiro, Ken Haruma, Hirofumi Kawamoto. Predictors of Atherosclerotic Cardiovascular Disease Events in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease. Internal Medicine 2024; doi: 10.2169/internalmedicine.4373-24
|
40 |
Idris Adewale Ahmed, Maryam Abimbola Mikail, Muhammad Ibrahim. Baccaurea angulata fruit juice ameliorates altered hematological and biochemical biomarkers in diet-induced hypercholesterolemic rabbits. Nutrition Research 2017; 42: 31 doi: 10.1016/j.nutres.2017.04.012
|
41 |
Yaron Ilan. Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need?. Digestive Diseases and Sciences 2018; 63(7): 1726 doi: 10.1007/s10620-018-5080-x
|
42 |
Gavin Hamilton, Michael S. Middleton, Elhamy R. Heba, Claude B. Sirlin. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019; : 141 doi: 10.1007/978-3-030-11748-1_6
|
43 |
Eric J. Lawitz, Bal Raj Bhandari, Peter J. Ruane, Anita Kohli, Eliza Harting, Dora Ding, Jen-Chieh Chuang, Ryan S. Huss, Chuhan Chung, Robert P. Myers, Rohit Loomba. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clinical Gastroenterology and Hepatology 2023; 21(1): 143 doi: 10.1016/j.cgh.2021.12.044
|
44 |
Stefano Ballestri, Claudio Tana, Maria Di Girolamo, Maria Cristina Fontana, Mariano Capitelli, Amedeo Lonardo, Giorgio Cioni. Semi-Quantitative Ultrasonographic Evaluation of NAFLD. Current Pharmaceutical Design 2020; 26(32): 3915 doi: 10.2174/1381612826666200417142444
|
45 |
Feitong Wu, Katja Pahkala, Markus Juonala, Johanna Jaakkola, Suvi P. Rovio, Terho Lehtimäki, Matthew A. Sabin, Antti Jula, Nina Hutri-Kähönen, Tomi Laitinen, Jorma S.A. Viikari, Costan G. Magnussen, Olli T. Raitakari. Childhood and Adulthood Passive Smoking and Nonalcoholic Fatty Liver in Midlife: A 31-year Cohort Study. American Journal of Gastroenterology 2021; 116(6): 1256 doi: 10.14309/ajg.0000000000001141
|
46 |
Eun Yeong Choe, Yong‐ho Lee, Young Ju Choi, Byung Wook Huh, Byung‐Wan Lee, Soo‐Kyung Kim, Eun Seok Kang, Bong‐Soo Cha, Eun Jig Lee, Kap Bum Huh, Zobair M Younossi. Waist‐to‐calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. Journal of Gastroenterology and Hepatology 2018; 33(5): 1082 doi: 10.1111/jgh.14011
|
47 |
Sonal Sharma, Abraham Sonny, Adam A. Dalia, Kunal Karamchandani. Acute heart failure after liver transplantation: A narrative review. Clinical Transplantation 2020; 34(11) doi: 10.1111/ctr.14079
|
48 |
Doaa El Amrousy, Heba EL Ashry, Sara Maher, Yousef Elsayed, Karim Elkashlan, Dina Abdelhai, Wegdan Mawlana, Samir Hasan. Increased inter-atrial and intra-atrial conduction times in pediatric patients with non-alcoholic fatty liver disease. European Journal of Pediatrics 2024; 183(12): 5489 doi: 10.1007/s00431-024-05809-8
|
49 |
Andrea Boccatonda, Lorenzo Andreetto, Damiano D’Ardes, Giulio Cocco, Ilaria Rossi, Susanna Vicari, Cosima Schiavone, Francesco Cipollone, Maria Teresa Guagnano. From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. Biomedicines 2023; 11(3): 883 doi: 10.3390/biomedicines11030883
|
50 |
Marcello Ricardo Paulista Markus, Peter J. Meffert, Sebastian Edgar Baumeister, Wolfgang Lieb, Ulrike Siewert, Sabine Schipf, Manja Koch, Jan A. Kors, Stephan Burkhard Felix, Marcus Dörr, Giovanni Targher, Henry Völzke. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population. Atherosclerosis 2016; 245: 123 doi: 10.1016/j.atherosclerosis.2015.12.023
|
51 |
Gavin Hamilton, Michael S. Middleton, Elhamy R. Heba, Claude B. Sirlin. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. 2015; : 99 doi: 10.1007/978-1-4471-4920-0_4
|
52 |
Amedeo Lonardo, Stefano Ballestri, Giovanni Targher, Paola Loria. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2015; 9(5): 629 doi: 10.1586/17474124.2015.965143
|
53 |
Amedeo Lonardo, Stefano Ballestri, Giovanni Guaraldi, Fabio Nascimbeni, Dante Romagnoli, Stefano Zona, Giovanni Targher. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World Journal of Gastroenterology 2016; 22(44): 9674-9693 doi: 10.3748/wjg.v22.i44.9674
|
54 |
|
55 |
Delbert Almerick T. Boncan, Yan Yu, Miaoru Zhang, Jie Lian, Varut Vardhanabhuti. Machine learning prediction of hepatic steatosis using body composition parameters: A UK Biobank Study. npj Aging 2024; 10(1) doi: 10.1038/s41514-023-00127-z
|
56 |
Stefano Ballestri, Fabio Nascimbeni, Dante Romagnoli, Amedeo Lonardo. The independent predictors of non‐alcoholic steatohepatitis and its individual histological features.. Hepatology Research 2016; 46(11): 1074 doi: 10.1111/hepr.12656
|
57 |
Yin Chan, Stephanie Pranke, Farid Rashidi, Shravan Nosib, Lawrence Worobetz. Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators. Canadian Journal of Gastroenterology and Hepatology 2017; 2017: 1 doi: 10.1155/2017/7298032
|
58 |
Ghodsiyeh Azarkar, Tayebeh Zeinali, Gholamreza Sharifzadeh, Farshid Abedi, Morteza Hajihosseini, Masood Ziaee. Prevalence of Non-Alcoholic Fatty Liver and its Related Factors in Birjand, During Year 2015. Modern Care Journal 2016; 13(4) doi: 10.5812/modernc.58829
|
59 |
Nicholas W.S. Chew, Bryan Chong, Cheng Han Ng, Gwyneth Kong, Yip Han Chin, Wang Xiao, Mick Lee, Yock Young Dan, Mark D. Muthiah, Roger Foo. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.971484
|
60 |
Amedeo Lonardo, Silvia Sookoian, Carlos J. Pirola, Giovanni Targher. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 2016; 65(8): 1136 doi: 10.1016/j.metabol.2015.09.017
|
61 |
Marta Bellesini, Matteo Bianchin, Chiara Corradi, Marco Paolo Donadini, Emanuel Raschi, Alessandro Squizzato. Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. Clinical Drug Investigation 2020; 40(11): 1001 doi: 10.1007/s40261-020-00962-y
|
62 |
Daniele Pastori, Licia Polimeni, Francesco Baratta, Arianna Pani, Maria Del Ben, Francesco Angelico. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease 2015; 47(1): 4 doi: 10.1016/j.dld.2014.07.170
|
63 |
Nirmalya Sinha, Saptarshi Mukhopadhyay, Manabendra Sau. Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity. Indian Journal of Gastroenterology 2020; 39(1): 75 doi: 10.1007/s12664-020-01020-3
|
64 |
Ivana Mikolasevic, Sandra Milic, Tamara Turk Wensveen, Ivana Grgic, Ivan Jakopcic, Davor Stimac, Felix Wensveen, Lidija Orlic. Nonalcoholic fatty liver disease - A multisystem disease?. World Journal of Gastroenterology 2016; 22(43): 9488-9505 doi: 10.3748/wjg.v22.i43.9488
|
65 |
Yasushi Honda, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Koji Fujita, Masato Yoneda, Toshiaki Takizawa, Satoru Saito, Yoji Nagashima, Atsushi Nakajima. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Scientific Reports 2017; 7(1) doi: 10.1038/srep42477
|
66 |
Leigang Wang, Yao Zhang, Bing Yu, Jianqi Zhao, Wenjing Zhang, Hongxuan Fan, Zhaoyu Ren, Bin Liang. The monocyte-to-high-density lipoprotein ratio is associated with the occurrence of atrial fibrillation among NAFLD patients: A propensity-matched analysis. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1127425
|
67 |
Olcay Ozveren, Cemil Izgi, Elif Eroglu, Mustafa Aytek Simsek, Ayca Turer, Zekeriya Kucukdurmaz, Veysel Cinar, Muzaffer Degertekin. Doppler Tissue Evaluation of Atrial Conduction Properties in Patients With Non-alcoholic Fatty-liver Disease. Ultrasonic Imaging 2016; 38(3): 225 doi: 10.1177/0161734615595015
|
68 |
Hasan Ali, Maryam Kazmi, Catherine Choi, Reza Hashemipour, Inderjit Singh, Nikolaos T Pyrsopoulos. In-Hospital Outcomes of Patients With Non-Alcoholic Fatty Liver Disease Who Underwent Percutaneous Coronary Intervention: A Nationwide Inpatient Sample Analysis. Cureus 2021; doi: 10.7759/cureus.17338
|
69 |
Alessandro Mantovani, Paolo Gisondi, Amedeo Lonardo, Giovanni Targher. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. International Journal of Molecular Sciences 2016; 17(2): 217 doi: 10.3390/ijms17020217
|
70 |
Daniele Pastori, Francesco Baratta, Marta Novo, Nicholas Cocomello, Francesco Violi, Francesco Angelico, Maria Del Ben. Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine 2018; 7(11): 378 doi: 10.3390/jcm7110378
|
71 |
Lisa B. VanWagner, Mary E. Rinella. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2016; 15(2): 75 doi: 10.1007/s11901-016-0295-9
|
72 |
Jorge Gutiérrez-Cuevas, Arturo Santos, Juan Armendariz-Borunda. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. International Journal of Molecular Sciences 2021; 22(21): 11629 doi: 10.3390/ijms222111629
|
73 |
Yun-Hua Li, Lu-Hua Yang, Kai-Hui Sha, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World Journal of Gastroenterology 2015; 21(22): 7008-7013 doi: 10.3748/wjg.v21.i22.7008
|
74 |
Dan Wang, Duo-Chun Ji, Chun-Yan Yu, Dan-Ni Wu, Ling Qi. Research progress on the mitochondrial mechanism of age-related non-alcoholic fatty liver. World Journal of Gastroenterology 2023; 29(13): 1982-1993 doi: 10.3748/wjg.v29.i13.1982
|
75 |
M. Hachemi, S. Benmakhlouf, P. Prost, N. Santolaria, X. Tchenio, N. Sedillot, F. Zoulim. La Non Alcoholic Fatty Liver Disease (NAFLD) et la Non Alcoholic Steato-Hepatitis (NASH) des pathologies de système : revue pour le réanimateur. Médecine Intensive Réanimation 2016; doi: 10.1007/s13546-016-1253-9
|
76 |
Sonal Sharma, Jonathan G. Stine, Thomas Verbeek, Dmitri Bezinover. Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. Journal of Cardiothoracic and Vascular Anesthesia 2022; 36(8): 2616 doi: 10.1053/j.jvca.2021.07.020
|
77 |
Reddemma Sandireddy, Suganya Sakthivel, Priyanka Gupta, Jatin Behari, Madhulika Tripathi, Brijesh Kumar Singh. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Frontiers in Cell and Developmental Biology 2024; 12 doi: 10.3389/fcell.2024.1433857
|
78 |
Zipeng Liu, Rufeng Wei, Yan Li. Coronary heart disease is associated with nonalcoholic fatty liver disease in patients without hypertension and diabetes. Medicine 2020; 99(26): e20898 doi: 10.1097/MD.0000000000020898
|
79 |
Jeffrey B. Schwimmer. Clinical advances in pediatric nonalcoholic fatty liver disease. Hepatology 2016; 63(5): 1718 doi: 10.1002/hep.28441
|
80 |
Aki J. Käräjämäki, Olli-Pekka Pätsi, Markku Savolainen, Y. Antero Kesäniemi, Heikki Huikuri, Olavi Ukkola, Giovanni Targher. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLOS ONE 2015; 10(11): e0142937 doi: 10.1371/journal.pone.0142937
|
81 |
Giovanni Targher, Christopher D. Byrne, Amedeo Lonardo, Giacomo Zoppini, Corrado Barbui. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology 2016; 65(3): 589 doi: 10.1016/j.jhep.2016.05.013
|
82 |
Edison Roberto PARISE. NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), MORE THAN A LIVER DISEASE. Arquivos de Gastroenterologia 2019; 56(3): 243 doi: 10.1590/s0004-2803.201900000-45
|
83 |
Shankar Baskar, Simone Jhaveri, Naim Alkhouri. Cardiovascular risk in pediatric nonalcoholic fatty liver disease: recent advances. Clinical Lipidology 2015; 10(4): 351 doi: 10.2217/clp.15.26
|
84 |
Kerim Esenboğa, Alparslan Kurtul, Hüseyin Nazman, Cemre Gül Tekin, Nil Özyüncü, Türkan Seda Tan, Eralp Tutar, Sibel Tekin Turhan. Evaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Disease. Angiology 2022; 73(1): 73 doi: 10.1177/00033197211005590
|
85 |
Marwa O. El-Derany, Sherihan G. AbdelHamid. Bone Marrow Mesenchymal Stem Cells and Their Derived Extracellular Vesicles Attenuate Non-Alcoholic Steatohepatitis-Induced Cardiotoxicity via Modulating Cardiac Mechanisms. Life 2022; 12(3): 355 doi: 10.3390/life12030355
|
86 |
Ya-Hui Ding, Yuan Ma, Lin-Yan Qian, Qiang Xu, Li-Hong Wang, Dong-Sheng Huang, Hai Zou. Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. Oncotarget 2017; 8(36): 60673 doi: 10.18632/oncotarget.19522
|
87 |
Min Kyu Kang, Jung Gil Park, Min Cheol Kim. Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Yonsei Medical Journal 2020; 61(10): 860 doi: 10.3349/ymj.2020.61.10.860
|
88 |
Theodosios D. Filippatos, Evangelos N. Liberopoulos, Moses S. Elisaf. Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism 2015; 6(1): 29 doi: 10.1177/2042018814558243
|
89 |
Mehmet Sayiner, Tamoore Arshad, Pegah Golabi, James Paik, Freba Farhat, Zobair M. Younossi. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. Hepatology International 2020; 14(4): 556 doi: 10.1007/s12072-020-10038-w
|
90 |
Stefano Ballestri, Fabio Nascimbeni, Dante Romagnoli, Enrica Baldelli, Giovanni Targher, Amedeo Lonardo. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection—Liver: The “Musketeer” in the Spotlight. International Journal of Molecular Sciences 2016; 17(3): 355 doi: 10.3390/ijms17030355
|
91 |
R. G. Myazin. Nafld and cardiovascular risks: clinic, diagnostic, features of therapy. Medical Council 2019; (12): 82 doi: 10.21518/2079-701X-2019-12-82-86
|
92 |
Catherine J. Kerr, Sally P. Waterworth, David Brodie, Gavin R. H. Sandercock, Lee Ingle. The associations between physical activity intensity, cardiorespiratory fitness, and non‐alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2021; 36(12): 3508 doi: 10.1111/jgh.15672
|
93 |
Gökay Taylan, Mustafa Ebik, Serdar Solak, Çağlar Kaya, Kenan Yalta. Risk of premature coronary atherosclerosis in patients with nonalcoholic fatty liver disease. Revista da Associação Médica Brasileira 2022; 68(10): 1428 doi: 10.1590/1806-9282.20220514
|
94 |
Salvatore Petta, Luca Valenti, Elisabetta Bugianesi, Giovanni Targher, Stefano Bellentani, Ferruccio Bonino, Ele Ferrannini, Carmela Loguercio, Amedeo Lonardo, Fabio Marra, Marcello Mancini, Luca Miele, Valerio Nobili, Gianluca Svegliati Baroni, Federico Alessandro, Stefano Ballestri, Maurizia Rossana Brunetto, Barbara Coco, Antonio Grieco, Silvia Fargion, Loreta Kondili, Fabio Nascimbeni, Anna Prinster, Dante Romagnoli, Stefano Taddei, Ester Vanni, Stefano Vella. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease 2016; 48(3): 333 doi: 10.1016/j.dld.2015.10.027
|
95 |
V. V. Skvortsov, A. V. Tumarenko, E. V. Belyakova, E. M. Skvortsova. Electrocardiographic changes in patients with non-alcoholic fatty liver disease. Spravočnik vrača obŝej praktiki (Journal of Family Medicine) 2023; (4): 25 doi: 10.33920/med-10-2304-04
|
96 |
Shihui Chen, Xiaolan Zhao, Li Ran, Jing Wan, Xiaofang Wang, Yu Qin, Furong Shu, Yanxiang Gao, Lijia Yuan, Qianyong Zhang, Mantian Mi. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Digestive and Liver Disease 2015; 47(3): 226 doi: 10.1016/j.dld.2014.11.015
|
97 |
Chiara Pisetta, Claudia Chillè, Giovanni Pelizzari, Marie Graciella Pigozzi, Massimo Salvetti, Anna Paini, Maria Lorenza Muiesan, Carolina De Ciuceis, Chiara Ricci, Damiano Rizzoni. Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease. High Blood Pressure & Cardiovascular Prevention 2020; 27(4): 321 doi: 10.1007/s40292-020-00389-8
|
98 |
Romain Itier, Maeva Guillaume, Jean‐Etienne Ricci, François Roubille, Nicolas Delarche, François Picard, Michel Galinier, Jérôme Roncalli. Non‐alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Failure 2021; 8(2): 789 doi: 10.1002/ehf2.13222
|
99 |
CHUANZHENG SUN, FEIZHOU HUANG, XUNYANG LIU, XUEFEI XIAO, MINGSHI YANG, GUI HU, HUAIZHENG LIU, LIANGKAN LIAO. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. International Journal of Molecular Medicine 2015; 35(3): 847 doi: 10.3892/ijmm.2015.2076
|
100 |
Salvatore Greco, Michele Campigotto, Andrea D’Amuri, Nicolò Fabbri, Angelina Passaro. Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review. Journal of Clinical Medicine 2024; 13(9): 2714 doi: 10.3390/jcm13092714
|
101 |
Marie Boyle, Quentin M. Anstee. Evidence‐based Gastroenterology and Hepatology 4e. 2019; : 523 doi: 10.1002/9781119211419.ch35
|
102 |
Alessandro Mantovani, Antonio Rigamonti, Stefano Bonapace, Bruna Bolzan, Matteo Pernigo, Giovanni Morani, Lorenzo Franceschini, Corinna Bergamini, Lorenzo Bertolini, Filippo Valbusa, Riccardo Rigolon, Isabella Pichiri, Giacomo Zoppini, Enzo Bonora, Francesco Violi, Giovanni Targher. Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. Diabetes Care 2016; 39(8): 1416 doi: 10.2337/dc16-0091
|
103 |
Yan Song, Ying Dang, Ping Wang, Gang Tian, Litao Ruan. CHD is Associated With Higher Grades of NAFLD Predicted by Liver Stiffness. Journal of Clinical Gastroenterology 2020; 54(3): 271 doi: 10.1097/MCG.0000000000001238
|
104 |
Alessandro Mantovani, Matteo Pernigo, Corinna Bergamini, Stefano Bonapace, Paola Lipari, Filippo Valbusa, Lorenzo Bertolini, Luciano Zenari, Isabella Pichiri, Marco Dauriz, Giacomo Zoppini, Enrico Barbieri, Christopher D. Byrne, Enzo Bonora, Giovanni Targher. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 2015; 64(8): 879 doi: 10.1016/j.metabol.2015.04.003
|
105 |
Eman M. Hasan, Rasha A. Abd Al Aziz, Dina Sabry, Hedy A. Badary, Yasmine Gaber, Ayman Yosry, Zeinab Zakaria. The association of adiponectin gene polymorphisms with susceptibility and progression of NAFLD in a cohort of Egyptian patients. Egyptian Liver Journal 2021; 11(1) doi: 10.1186/s43066-021-00103-w
|
106 |
Nwe Ni Than, Philip N. Newsome. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015; 239(1): 192 doi: 10.1016/j.atherosclerosis.2015.01.001
|
107 |
Tiangui Li, Peng Wang, Xiao Gong, Weelic Chong, Yang Hai, Chao You, Juan Kang, Fang Fang, Yu Zhang. Prevalence and Prognostic Significance of Liver Fibrosis in Patients With Aneurysmal Subarachnoid Hemorrhage. Frontiers in Neurology 2022; 13 doi: 10.3389/fneur.2022.850405
|
108 |
Roberto B Bazotte, Lorena G Silva, Fabiana PM Schiavon. Insulin resistance in the liver: Deficiency or excess of insulin?. Cell Cycle 2014; 13(16): 2494 doi: 10.4161/15384101.2014.947750
|
109 |
Laura S. Chiu, Alison Pedley, Joseph M. Massaro, Emelia J. Benjamin, Gary F. Mitchell, David D. McManus, Jayashri Aragam, Ramachandran S. Vasan, Susan Cheng, Michelle T. Long. The association of non‐alcoholic fatty liver disease and cardiac structure and function—Framingham Heart Study. Liver International 2020; 40(10): 2445 doi: 10.1111/liv.14600
|
110 |
Valerio Rosato, Mario Masarone, Andrea Aglitti, Marcello Persico. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020; 1(5) doi: 10.37349/emed.2020.00018
|
111 |
Amedeo Lonardo, Stefano Ballestri. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020; 1(3): 85 doi: 10.37349/emed.2020.00007
|
112 |
Banrida Wahlang, Jazmyne Barney, Brendan Thompson, Chunyan Wang, Omer M Hamad, Jessie B Hoffman, Michael C Petriello, Andrew J Morris, Bernhard Hennig. Editor’s Highlight: PCB126 Exposure Increases Risk for Peripheral Vascular Diseases in a Liver Injury Mouse Model. Toxicological Sciences 2017; 160(2): 256 doi: 10.1093/toxsci/kfx180
|
113 |
Kevan Josloff, Jacob Beiriger, Adnan Khan, Richard J. Gawel, Richard S. Kirby, Aaron D. Kendrick, Abhinav K. Rao, Roy X. Wang, Michelle M. Schafer, Margaret E. Pearce, Kashyap Chauhan, Yash B. Shah, Gregary D. Marhefka, Dina Halegoua-DeMarzio. Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. Journal of Cardiovascular Development and Disease 2022; 9(12): 419 doi: 10.3390/jcdd9120419
|
114 |
Marco Bertolotti, Amedeo Lonardo, Chiara Mussi, Enrica Baldelli, Elisa Pellegrini, Stefano Ballestri, Dante Romagnoli, Paola Loria. Nonalcoholic fatty liver disease and aging: Epidemiology to management. World Journal of Gastroenterology 2014; 20(39): 14185-14204 doi: 10.3748/wjg.v20.i39.14185
|
115 |
Tamoore Arshad, Pegah Golabi, James Paik, Alita Mishra, Zobair M. Younossi. Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population. Hepatology Communications 2019; 3(1): 74 doi: 10.1002/hep4.1285
|
116 |
Jonathan Zhi Kai Toh, Xin-Hui Pan, Phoebe Wen Lin Tay, Cheng Han Ng, Jie Ning Yong, Jieling Xiao, Jin Hean Koh, En Ying Tan, Eunice Xiang Xuan Tan, Yock Young Dan, Poay Huan Loh, Roger Foo, Nicholas W.S. Chew, Arun J. Sanyal, Mark D. Muthiah, Mohammad Shadab Siddiqui. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2022; 20(11): 2462 doi: 10.1016/j.cgh.2021.09.021
|
117 |
Claudio Tana, Stefano Ballestri, Fabrizio Ricci, Angelo Di Vincenzo, Andrea Ticinesi, Sabina Gallina, Maria Adele Giamberardino, Francesco Cipollone, Richard Sutton, Roberto Vettor, Artur Fedorowski, Tiziana Meschi. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. International Journal of Environmental Research and Public Health 2019; 16(17): 3104 doi: 10.3390/ijerph16173104
|
118 |
Tahmineh Tavakoli, Toba Kazemi, Homa Mollaei, Fatemeh Salmani, Samira Saghafi, Ensiah Sadat Mousavi, Mahyar Mohamadifard, Gholamreza Sharifzadeh. The Relationship Between the Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) with the Severity of Coronary Artery Disease (CAD) in Patients Undergoing Coronary Artery Angiography: A Cross- Sectional Study. Iranian Red Crescent Medical Journal 2018; 20(6) doi: 10.5812/ircmj.58369
|
119 |
Anna Ludovica Fracanzani, Silvia Tiraboschi, Giuseppina Pisano, Dario Consonni, Andrea Baragetti, Cristina Bertelli, Danilo Norata, Luca Valenti, Liliana Grigore, Marianna Porzio, Alberico Catapano, Silvia Fargion. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 2016; 246: 208 doi: 10.1016/j.atherosclerosis.2016.01.016
|
120 |
Carlos Millán-Rodríguez, Carlos Palacios Castelló Palacios Castelló, María de Regla Caballero-Valderrama, Gonzalo Barón Esquivias. Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist. European Cardiology Review 2023; 18 doi: 10.15420/ecr.2023.22
|
121 |
Zhihong Ma, Li Chu, Hongying Liu, Jieru Li, Yuanyuan Zhang, Wentai Liu, Jun Dai, Jianfeng Yi, Yue Gao. Paeoniflorin alleviates non-alcoholic steatohepatitis in rats: Involvement with the ROCK/NF-κB pathway. International Immunopharmacology 2016; 38: 377 doi: 10.1016/j.intimp.2016.06.023
|
122 |
Vasilios G Athyros, Konstantinos Tziomalos, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Dimitri P Mikhailidis. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology 2015; 21(22): 6820-6834 doi: 10.3748/wjg.v21.i22.6820
|
123 |
Giovanni Targher, Maurizio Rossini, Amedeo Lonardo. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. Endocrine 2016; 51(2): 211 doi: 10.1007/s12020-015-0640-8
|
124 |
Umair Iqbal, Brandon J. Perumpail, Nimy John, Sandy Sallam, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, Aijaz Ahmed. Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases 2018; 6(4): 87 doi: 10.3390/diseases6040087
|
125 |
Zheng Bao, Xue Wang, Yuhong Li, Fumin Feng. Vitamin D Alleviates Cognitive Dysfunction by Activating the VDR/ERK1/2 Signaling Pathway in an Alzheimer’s Disease Mouse Model. Neuroimmunomodulation 2020; 27(4): 178 doi: 10.1159/000510400
|
126 |
Søren Møller, Signe Wiese, Mads Barløse, Jens D. Hove. How non-alcoholic fatty liver disease and cirrhosis affect the heart. Hepatology International 2023; 17(6): 1333 doi: 10.1007/s12072-023-10590-1
|
127 |
G. Targher, A. Lonardo, M. Rossini. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. Journal of Endocrinological Investigation 2015; 38(8): 817 doi: 10.1007/s40618-015-0315-6
|
128 |
Luca Miele, Maria Adele Alberelli, Maurizio Martini, Antonio Liguori, Giuseppe Marrone, Alessandra Cocomazzi, Fabio Maria Vecchio, Raffaele Landolfi, Antonio Gasbarrini, Antonio Grieco, Erica De Candia. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Translational Research 2021; 231: 24 doi: 10.1016/j.trsl.2020.11.003
|
129 |
Christopher M. Milroy. Fatty Liver and the Forensic Pathologist. Academic Forensic Pathology 2018; 8(2): 296 doi: 10.1177/1925362118782061
|
130 |
Minyoul Baik, Hyo Suk Nam, Ji Hoe Heo, Hyung Jong Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Hye Sun Lee, Seung Up Kim, Young Dae Kim. Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. Cerebrovascular Diseases 2020; 49(5): 474 doi: 10.1159/000510436
|
131 |
A. V. Nelidova, M. A. Livzan, N. A. Nikolaev, T. S. Krolevets. Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy. Rational Pharmacotherapy in Cardiology 2022; 17(6): 880 doi: 10.20996/1819-6446-2021-12-14
|
132 |
Francesco Baratta, Daniele Pastori, Licia Polimeni, Giulia Tozzi, Francesco Violi, Francesco Angelico, Maria Del Ben. Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. International Journal of Molecular Sciences 2015; 16(12): 28014 doi: 10.3390/ijms161226085
|
133 |
Mohammad Ghasem Han, Masoud Cina, Mehrnoush Zakerkish, Fakher Rahim, Amal Saki-Maleh, Qasem Nissi. Correlation between Non-Alcoholic Fatty Liver Disease and Carotid Intima-Media Thickness in Patient with Type II Diabetes. International Journal of Osteoporosis and Metabolic Disorders 2015; 8(2): 35 doi: 10.3923/ijom.2015.35.41
|
134 |
素珀 刘. Investigation of Fatty Liver and Cardiovascular Risk Factors on Civil Servants’ of a Town in Beijing Daxing District. Asian Case Reports in Vascular Medicine 2017; 5(03): 15 doi: 10.12677/ACRVM.2017.53003
|
135 |
Francis Chanda, Kai-xuan Lin, Abdallah Iddy Chaurembo, Jian-yuan Huang, Hui-juan Zhang, Wen-hui Deng, Yun-jing Xu, Yuan Li, Li-dan Fu, Hao-dong Cui, Chi Shu, Yang Chen, Na Xing, Han-bin Lin. PM2.5-mediated cardiovascular disease in aging: Cardiometabolic risks, molecular mechanisms and potential interventions. Science of The Total Environment 2024; 954: 176255 doi: 10.1016/j.scitotenv.2024.176255
|
136 |
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8): 1109 doi: 10.1016/j.metabol.2016.05.003
|
137 |
Annachiara Pingitore, Camillo Autore, Mariangela Peruzzi, Elena Cavarretta. Non-alcoholic fatty liver disease and heart valve disease: a neglected link. Minerva Cardioangiologica 2020; 68(6) doi: 10.23736/S0026-4725.20.05161-0
|
138 |
Fabio Nascimbeni, Dante Romagnoli, Stefano Ballestri, Enrica Baldelli, Simonetta Lugari, Valentina Sirotti, Valentina Giampaoli, Amedeo Lonardo. Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?. Diseases 2018; 6(1): 17 doi: 10.3390/diseases6010017
|
139 |
Stefano Ballestri, Mariano Capitelli, Maria Cristina Fontana, Dimitriy Arioli, Elisa Romagnoli, Catia Graziosi, Amedeo Lonardo, Marco Marietta, Francesco Dentali, Giorgio Cioni. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Advances in Therapy 2020; 37(5): 1910 doi: 10.1007/s12325-020-01307-z
|
140 |
Andreea-Manuela Mirea, Rinke Stienstra, Thirumala-Devi Kanneganti, Cees J. Tack, Triantafyllos Chavakis, Erik J.M. Toonen, Leo A.B. Joosten. Mice Deficient in the IL-1β Activation Genes Prtn3, Elane, and Casp1 Are Protected Against the Development of Obesity-Induced NAFLD. Inflammation 2020; 43(3): 1054 doi: 10.1007/s10753-020-01190-4
|
141 |
Effect of omega-3 polyunsaturated fatty acids on blood lipid profile, leptin level and endothelial function in patients with ischemic heart disease in combination with non-alcoholic steatosis of the liver. Family medicine 2018; (3): 19 doi: 10.30841/2307-5112.3.2018.146288
|
142 |
Keungmo Yang, Myeongjun Song. New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk. Nutrients 2023; 15(18): 3970 doi: 10.3390/nu15183970
|
143 |
Alessandro Mantovani, Matteo Pernigo, Corinna Bergamini, Stefano Bonapace, Paola Lipari, Isabella Pichiri, Lorenzo Bertolini, Filippo Valbusa, Enrico Barbieri, Giacomo Zoppini, Enzo Bonora, Giovanni Targher, Xiongwen Chen. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLOS ONE 2015; 10(8): e0135329 doi: 10.1371/journal.pone.0135329
|
144 |
Alexandra Jichitu, Simona Bungau, Ana Maria Alexandra Stanescu, Cosmin Mihai Vesa, Mirela Marioara Toma, Cristiana Bustea, Stela Iurciuc, Marius Rus, Nicolae Bacalbasa, Camelia Cristina Diaconu. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics 2021; 11(4): 689 doi: 10.3390/diagnostics11040689
|
145 |
Dmitri Bezinover, Ahmed Mukhtar, Gebhard Wagener, Christopher Wray, Annabel Blasi, Kate Kronish, Jeron Zerillo, Dana Tomescu, Aliaksei Pustavoitau, Marina Gitman, Anil Singh, Fuat H. Saner. Hemodynamic Instability During Liver Transplantation in Patients With End-stage Liver Disease: A Consensus Document from ILTS, LICAGE, and SATA. Transplantation 2021; 105(10): 2184 doi: 10.1097/TP.0000000000003642
|
146 |
Rajesh Parsanathan, Sushil K. Jain. Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases. Metabolic Syndrome and Related Disorders 2020; 18(1): 10 doi: 10.1089/met.2019.0073
|
147 |
M. A. Osadchuk, E. D. Mironova. Non-viral liver diseases: pathogenetic approaches to therapy. Medical alphabet 2019; 3(20): 30 doi: 10.33667/2078-5631-2019-2-20(395)-30-36
|
148 |
Marina Gitman, Megan Albertz, Ramona Nicolau‐Raducu, Stephen Aniskevich, Sher‐Lu Pai. Cardiac diseases among liver transplant candidates. Clinical Transplantation 2018; 32(7) doi: 10.1111/ctr.13296
|
149 |
Mengyao Zhao, Shumin Chen, Xiaoguo Ji, Xin Shen, Jiangshan You, Xinyi Liang, Hao Yin, Liming Zhao. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacological Research 2021; 166: 105517 doi: 10.1016/j.phrs.2021.105517
|
150 |
Anoop Tiwari, Surendra G, Soumya Meka, Bincy Varghese, Gayatri Vishwakarma, Ramu Adela. The effect of Nigella sativa on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Human Nutrition & Metabolism 2022; 28: 200146 doi: 10.1016/j.hnm.2022.200146
|
151 |
Xinxu Yuan, Owais M. Bhat, Yao Zou, Yang Zhang, Pin-Lan Li. Contribution of Hepatic Steatosis–Intensified Extracellular Vesicle Release to Aggravated Inflammatory Endothelial Injury in Liver-Specific Asah1 Gene Knockout Mice. The American Journal of Pathology 2023; 193(4): 493 doi: 10.1016/j.ajpath.2022.12.007
|
152 |
Giovanni Catalano, Odysseas P. Chatzipanagiotou, Jun Kawashima, Timothy M. Pawlik. Metabolic-associated steatotic liver disease and hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2024; 25(17): 2283 doi: 10.1080/14656566.2024.2426680
|
153 |
YipHan Chin, Jieyu Lim, Gwyneth Kong, Cheng Han Ng, Rachel Goh, Mark Muthiah, Anurag Mehta, Bryan Chong, Chaoxing Lin, Kai En Chan, William Kong, Kian Keong Poh, Roger Foo, Ping Chai, Tiong‐Cheng Yeo, Adrian F. Low, Chi Hang Lee, Huay Cheem Tan, Mark Yan‐Yee Chan, A Mark Richards, Poay‐Huan Loh, Nicholas W. S. Chew. Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction. Diabetes, Obesity and Metabolism 2023; 25(4): 1032 doi: 10.1111/dom.14950
|
154 |
|
155 |
Lisa B. VanWagner, Jane E. Wilcox, Laura A. Colangelo, Donald M. Lloyd‐Jones, J. Jeffrey Carr, Joao A. Lima, Cora E. Lewis, Mary E. Rinella, Sanjiv J. Shah. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population‐based study. Hepatology 2015; 62(3): 773 doi: 10.1002/hep.27869
|
156 |
Giuseppina Pisano, Rosa Lombardi, Anna Fracanzani. Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin. International Journal of Molecular Sciences 2016; 17(5): 675 doi: 10.3390/ijms17050675
|
157 |
Ioana Mozos. Arrhythmia risk in liver cirrhosis. World Journal of Hepatology 2015; 7(4): 662-672 doi: 10.4254/wjh.v7.i4.662
|
158 |
Kazuhiro Osawa, Toru Miyoshi, Kentarou Yamauchi, Yasushi Koyama, Kazufumi Nakamura, Shuhei Sato, Susumu Kanazawa, Hiroshi Ito, Giovanni Targher. Nonalcoholic Hepatic Steatosis Is a Strong Predictor of High-Risk Coronary-Artery Plaques as Determined by Multidetector CT. PLOS ONE 2015; 10(6): e0131138 doi: 10.1371/journal.pone.0131138
|
159 |
Rupak Desai, Ali Tariq Alvi, Advait Vasavada, Yashwitha Sai Pulakurthi, Bhavin Patel, Adil Sarvar Mohammed, Shreyans Doshi, Ikechukwu Ogbu. Sex and racial disparities in non-alcoholic fatty liver disease-related cardiovascular events: National inpatient sample analysis (2019). World Journal of Cardiology 2024; 16(3): 137-148 doi: 10.4330/wjc.v16.i3.137
|
160 |
Enea Bonci, Claudio Chiesa, Paolo Versacci, Caterina Anania, Lucia Silvestri, Lucia Pacifico. Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/213737
|
161 |
Tilmann Graeter, Pia C. Niedermayer, Richard A. Mason, Suemeyra Oeztuerk, Mark M. Haenle, Wolfgang Koenig, Bernhard Otto Boehm, Wolfgang Kratzer. Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Research Notes 2015; 8(1) doi: 10.1186/s13104-015-1645-3
|
162 |
Helen L. Reeves, Marco Y. W. Zaki, Christopher P. Day. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Digestive Diseases and Sciences 2016; 61(5): 1234 doi: 10.1007/s10620-016-4085-6
|
163 |
Lijun Hu, Xiaoliang Shao, Chun Qiu, Xiaonan Shao, Xiaosong Wang, Rong Niu, Yuetao Wang. Hepatic steatosis is associated with abnormal hepatic enzymes, visceral adiposity, altered myocardial glucose uptake measured by 18F-FDG PET/CT. BMC Endocrine Disorders 2020; 20(1) doi: 10.1186/s12902-020-00556-x
|
164 |
Gerardo Rodriguez-Araujo, Andrew J. Krentz. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019; : 275 doi: 10.1007/978-3-030-11748-1_11
|
165 |
Shelley E. Keating, Daniel A. Hackett, Helen M. Parker, Kimberley L. Way, Helen T. O'Connor, Amanda Sainsbury, Michael K. Baker, Vivienne H. Chuter, Ian D. Caterson, Jacob George, Nathan A. Johnson. Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial. Hepatology Research 2017; 47(7): 622 doi: 10.1111/hepr.12781
|
166 |
Safa Hoodeshenas, Meng Yin, Sudhakar Kundapur Venkatesh. Magnetic Resonance Elastography of Liver. Topics in Magnetic Resonance Imaging 2018; 27(5): 319 doi: 10.1097/RMR.0000000000000177
|
167 |
Sebastian Beer, Jonas Babel, Neef Martin, Valentin Blank, Johannes Wiegand, Thomas Karlas, Shunsuke Mori. Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease. PLOS ONE 2023; 18(9): e0286882 doi: 10.1371/journal.pone.0286882
|
168 |
Xue Wang, Jinlong You, Jing Tang, Xiuqian Li, Rui Wang, Yuanyuan Li, Yana Bai, Minzhen Wang, Shan Zheng. Interaction between non-alcoholic fatty liver disease and obesity on the risk of developing cardiovascular diseases. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-74841-3
|
169 |
Xiaoxia Wang, Yuchuan Tan, Daihong Liu, Hesong Shen, Yongchun Deng, Yong Tan, Lei Wang, Yipeng Zhang, Xin Ma, Xiaohua Zeng, Jiuquan Zhang. Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy. European Radiology 2022; 32(7): 4898 doi: 10.1007/s00330-022-08581-1
|
170 |
Dawn Swan, Ton Lisman, Armando Tripodi, Jecko Thachil. The prothrombotic tendency of metabolic-associated fatty liver disease. Journal of Thrombosis and Haemostasis 2023; 21(11): 3045 doi: 10.1016/j.jtha.2023.06.017
|
171 |
Emma Toh, Priscilla Joseph Ravi, Chua Ming, Amanda Lim, Ching-Hui Sia, Bernard Chan, Vijay Sharma, Cheng Ng, Eunice Tan, Leonard Yeo, Daniel Huang, Mark Muthiah, Benjamin Tan. Risk of Liver Fibrosis Is Associated with More Severe Strokes, Increased Complications with Thrombolysis, and Mortality. Journal of Clinical Medicine 2023; 12(1): 356 doi: 10.3390/jcm12010356
|
172 |
Amedeo Lonardo, Fabio Nascimbeni, Alessandro Mantovani, Giovanni Targher. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. Journal of Hepatology 2018; 68(2): 335 doi: 10.1016/j.jhep.2017.09.021
|
173 |
Wei-Chin Hung, Teng-Hung Yu, Cheng-Ching Wu, Thung-Lip Lee, Wei-Hua Tang, Chia-Chi Chen, I-Cheng Lu, Fu-Mei Chung, Yau-Jiunn Lee, Chia-Chang Hsu. Nonalcoholic Fatty Liver Disease Is Related to Abnormal Corrected QT Interval and Left Ventricular Hypertrophy in Chinese Male Steelworkers. International Journal of Environmental Research and Public Health 2022; 19(21): 14555 doi: 10.3390/ijerph192114555
|
174 |
Stefan Traussnigg, Emina Halilbasic, Harald Hofer, Petra Munda, Tatjana Stojakovic, Günter Fauler, Karl Kashofer, Martin Krssak, Michael Wolzt, Michael Trauner. Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. Wiener klinische Wochenschrift 2021; 133(9-10): 441 doi: 10.1007/s00508-020-01735-5
|
175 |
Min Xu, Xi‐Ming Zheng, Fang Jiang, Wei‐qiang Qiu. MicroRNA‐190b regulates lipid metabolism and insulin sensitivity by targeting IGF‐1 and ADAMTS9 in non‐alcoholic fatty liver disease. Journal of Cellular Biochemistry 2018; 119(7): 5864 doi: 10.1002/jcb.26776
|
176 |
Karn Wijarnpreecha, Boonphiphop Boonpheng, Charat Thongprayoon, Veeravich Jaruvongvanich, Patompong Ungprasert. The association between non-alcoholic fatty liver disease and atrial fibrillation: A meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2017; 41(5): 525 doi: 10.1016/j.clinre.2017.08.001
|
177 |
Pegah Golabi, Munkhzul Otgonsuren, Leyla de Avila, Mehmet Sayiner, Nila Rafiq, Zobair M. Younossi. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine 2018; 97(13): e0214 doi: 10.1097/MD.0000000000010214
|
178 |
Mohammad Dehghani Firouzabadi, Amirhossein Poopak, Ali Sheikhy, Fatemeh Dehghani Firouzabadi, Fatemeh Moosaie, Soghra Rabizadeh, Sara Momtazmanesh, Manouchehr Nakhjavani, Alireza Esteghamati, Basilio Pintaudi. Nonalcoholic Fatty Liver Disease as a Potential Risk Factor for Cardiovascular Disease in Patients with Type 2 Diabetes: A Prospective Cohort Study. International Journal of Endocrinology 2024; 2024(1) doi: 10.1155/2024/5328965
|
179 |
Ziheng Wei, Yurun Xue, Yucong Xue, Jie Cheng, Guoping Lv, Li Chu, Zhihong Ma, Shengjiang Guan. Ferulic acid attenuates non-alcoholic steatohepatitis by reducing oxidative stress and inflammation through inhibition of the ROCK/NF-κB signaling pathways. Journal of Pharmacological Sciences 2021; 147(1): 72 doi: 10.1016/j.jphs.2021.05.006
|
180 |
Jarkko S. Heiskanen, Saku Ruohonen, Suvi P. Rovio, Ville Kytö, Mika Kähönen, Terho Lehtimäki, Jorma S. A. Viikari, Markus Juonala, Tomi Laitinen, Päivi Tossavainen, Eero Jokinen, Nina Hutri‐Kähönen, Olli T. Raitakari. Determinants of left ventricular diastolic function—The Cardiovascular Risk in Young Finns Study. Echocardiography 2019; 36(5): 854 doi: 10.1111/echo.14321
|
181 |
Felix Schoenrath, Evgenij Potapov. Mechanical Support for Heart Failure. 2020; : 141 doi: 10.1007/978-3-030-47809-4_10
|
182 |
Reenam S. Khan, Philip N. Newsome. Non-alcoholic fatty liver disease and liver transplantation. Metabolism 2016; 65(8): 1208 doi: 10.1016/j.metabol.2016.02.013
|
183 |
Muzaffer Degertekin. Deterioration of Heart Rate Recovery Index in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Medical Science Monitor 2014; 20: 1539 doi: 10.12659/MSM.890741
|
184 |
Mehdi Birjandi, Seyyed Mohammad Taghi Ayatollahi, Saeedeh Pourahmad, Ali Reza Safarpour. Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iranian Red Crescent Medical Journal 2016; 18(11) doi: 10.5812/ircmj.32858
|
185 |
M. A. Livzan, O. V. Gaus, N. A. Nikolaev, T. S. Krolevetz. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology 2020; 1(10): 57 doi: 10.31146/1682-8658-ecg-170-10-57-65
|
186 |
Stefano Ballestri, Fabio Nascimbeni, Simonetta Lugari, Amedeo Lonardo, Giampiero Francica. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Review of Gastroenterology & Hepatology 2019; 13(7): 667 doi: 10.1080/17474124.2019.1621164
|
187 |
Marília Marques Pereira Lira, José Eymard Moraes de Medeiros Filho, Vinícius José Baccin Martins, Gitana da Silva, Francisco Antônio de Oliveira Junior, Éder Jackson Bezerra de Almeida Filho, Alexandre Sérgio Silva, João Henrique da Costa-Silva, José Luiz de Brito Alves, Oscar Millet. Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. PLOS ONE 2020; 15(8): e0237360 doi: 10.1371/journal.pone.0237360
|
188 |
Mohamed I. Elsaid, John F.P. Bridges, Na Li, Vinod K. Rustgi. Metabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease. Gastro Hep Advances 2022; 1(3): 445 doi: 10.1016/j.gastha.2022.02.002
|
189 |
Ugur Arslan, Mustafa Yenerçağ. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World Journal of Clinical Cases 2020; 8(20): 4688-4699 doi: 10.12998/wjcc.v8.i20.4688
|
190 |
Namra V Gohil, Nida Tanveer, Vijaya Krishna Makkena, Arturo P Jaramillo, Babatope L Awosusi, Javaria Ayyub, Karan Nareshbhai Dabhi, Tuheen Sankar Nath. Non-alcoholic Fatty Liver Disease and Its Association With Left Ventricular Diastolic Dysfunction: A Systematic Review. Cureus 2023; doi: 10.7759/cureus.43013
|
191 |
V. A. Akhmedov. Nonalcoholic fatty liver diseases as dramatic consequence of obesity. Medical alphabet 2019; 3(20): 37 doi: 10.33667/2078-5631-2019-2-20(395)-37-40
|
192 |
Lauren N. Woodie, Yuwen Luo, Michael J. Wayne, Emily C. Graff, Bulbul Ahmed, Ann Marie O'Neill, Michael W. Greene. Restricted feeding for 9 h in the active period partially abrogates the detrimental metabolic effects of a Western diet with liquid sugar consumption in mice. Metabolism 2018; 82: 1 doi: 10.1016/j.metabol.2017.12.004
|
193 |
Amandeep Singh, Phuc Le, Maajid M. Peerzada, Rocio Lopez, Naim Alkhouri. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients. Journal of Clinical Gastroenterology 2018; 52(3): 268 doi: 10.1097/MCG.0000000000000905
|
194 |
Chi‐Sheng Hung, Ping‐Huei Tseng, Chia‐Hung Tu, Chien‐Chuan Chen, Wei‐Chih Liao, Yi‐Chia Lee, Han‐Mo Chiu, Hung‐Ju Lin, Yi‐Lwun Ho, Wei‐Shiung Yang, Ming‐Shiang Wu, Ming‐Fong Chen. Nonalcoholic Fatty Liver Disease Is Associated With QT Prolongation in the General Population. Journal of the American Heart Association 2015; 4(7) doi: 10.1161/JAHA.115.001820
|
195 |
Licia Polimeni, Maria Del Ben, Francesco Baratta, Ludovica Perri, Fabiana Albanese, Daniele Pastori, Francesco Violi, Francesco Angelico. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World Journal of Hepatology 2015; 7(10): 1325-1336 doi: 10.4254/wjh.v7.i10.1325
|
196 |
Ruoran Wang, Linrui Cai, Yan Liu, Jing Zhang, Min He, Jianguo Xu. Liver fibrosis score is associated with the mortality of traumatic brain injury patients. Neurosurgical Review 2023; 46(1) doi: 10.1007/s10143-023-02095-0
|